SCHEMBL10067277

SCHEMBL10067277

Cc1c(-c2nc3c4cccnc4c4ncccc4c3[nH]2)c2ccccc2n1CC(=O)N1CCCC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
GLA P06280 1/20 0.50
MAPT P10636 5/20 0.45
TP53 P04637 3/20 0.44
THRB P10828 1/20 0.41
MAPK1 P28482 2/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TSHR P16473 4/20 0.38
ALDH1A1 P00352 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
GRIN2B Q13224 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10067281 0.99 LMNA (0.49) LMNAL3MBTL1GLAMAPTTP53
SCHEMBL10067295 0.99 LMNA (0.49) LMNAL3MBTL1GLAMAPTTP53
SCHEMBL10067306 0.91 TSHR (0.44) LMNAL3MBTL1GLAMAPTTP53
SCHEMBL10067278 0.87 TSHR (0.47) LMNAL3MBTL1GLAMAPTTP53
SCHEMBL10067267 0.79 MAPT (0.46) LMNAL3MBTL1MAPTTP53TSHR
SCHEMBL10067302 0.79 MAPT (0.48) LMNAL3MBTL1MAPTTP53TSHR
SCHEMBL10067272 0.79 MAPT (0.48) LMNAL3MBTL1MAPTTP53TSHR
SCHEMBL10067289 0.75 KDM4E (0.37) LMNAL3MBTL1GLAMAPTMAPK1
SCHEMBL10067342 0.74 LMNA (0.72) LMNAL3MBTL1GLAMAPTTP53
SCHEMBL10067310 0.73 KMT2A (0.48) LMNAL3MBTL1MAPTTP53NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 US disclosed
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer FLI1, IKZF3, IKZF2 LMNA 1875/4885L3MBTL1 440/4885GLA 2359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.